DSDenny Sakkas

Denny Sakkas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denny Sakkas has a total of 470 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epididymis-derived RNAs in sperm affect the next generation: potential clinical implications

    by Aidan J Chen, Alison J Meyers, Shannon Rainsford, Alexandre Champroux, Larry Feig, Denny Sakkas

    Until recently, the sole function of sperm was thought to be as delivery agents for the paternal contribution of zygote genes encoded in the DNA they carry. However, recent research has shown that sperm contribute substantially more information to oocytes upon fertilization through a select population of non-coding (nc)RNAs obtained while traversing the epididymis. Strikingly, their content can be altered by the environment in which males have lived, such as their exposure to various types of pollutants, traumas, addictive drugs, diet, and other factors. These changes in sperm ncRNA content can be responsible for transmitting the negative consequences of these environments to their offspring, via ‘epigenetic inheritance’, which is reminiscent of Lamarckian inheritance. This mini-review aims to provide an overview of the role of environment-regulated sperm ncRNAs in this process. We include studies on the relationship between specific paternal environments and the associated changes in sperm ncRNA content. These studies have been performed largely in rodent models, but we also describe evidence supporting the same processes occurring in humans. As an example, we focus on the epigenetic inheritance of stress phenotypes through changes in sperm miRNA profiles. We propose that identifying these specific ncRNAs carried by human sperm could lead to future diagnostic and treatment paradigms positively impacting ART. Screening out these potentially harmful sperm, or further research that provides approaches to reverse these changes before conception, may therefore prevent negative consequences related to epigenetic inheritance.

  • Open Access

    Metabolic imaging for gamete and embryo assessment through advanced microscopy technologies: a novel avenue for artificial intelligence?

    by Fabrizzio Horta, Denny Sakkas, Shannon Handley, Yaoxi Xiong, Bettina Mihalas, Rebecca Deans, Roger J Hart, Robert B Gilchrist, Ewa M Goldys

    Infertility affects approximately one in six people globally and demand for ARTs, is expected to rise as parenthood is increasingly delayed. However, ART success remains constrained by gamete and embryo quality, female age, and biological factors beyond chromosomal status alone, highlighting the need for non-invasive methods that can complement current morphology-based and genetic approaches. Because gamete and embryo developmental competence is tightly coupled to cellular metabolism, label-free metabolic imaging has emerged as a promising strategy to assess developmental potential through endogenous autofluorescence of reduced nicotinamide adenine dinucleotide/phosphate [NAD(P)H] and oxidized flavins (FAD), which provide optical proxies of redox balance, mitochondrial activity, and oxidative metabolism. This invited mini-review synthesizes the biochemical basis of NAD(P)H/FAD autofluorescence signals, relates these readouts to the unique metabolic programs of oocytes, embryos across preimplantation development, and sperm, and reviews reproductive studies using fluorescence lifetime imaging microscopy, hyperspectral microscopy, and emerging light-sheet fluorescence microscopy. We discuss practical and interpretive challenges, including modality-dependent signal biases and recent consensus efforts towards standardization. Evidence linking metabolic signatures to reproductive ageing, developmental potential, and embryo ploidy status suggests that metabolic imaging, particularly when paired with artificial intelligence (AI), could enable automated, objective decision support for gamete and embryo selection. Finally, we briefly outline how AI could convert complex metabolic imaging data into clinically interpretable decision-support outputs for embryo ranking and risk stratification. Advances in rapid volumetric imaging, microsystems, and AI may support future ART workflows aimed at improving efficiency, accessibility, and cost-effectiveness.

  • Open Access

    Can Cell-Free DNA in the Culture Medium Predict the Chromosomal Constitution of Preimplantation Embryos? Final Results from a Multicenter Study with 2539 Blastocysts

    by Luis Navarro-Sánchez, Denny Sakkas, Nilo Frantz, Emilio de la Fuente Lucena, William Venier, Daria Maria Soscia, Gerardo Barroso, Claudio Bisioli, Michael DiMattina, Bilgen Teke, et al.

    Background/Objectives: In the last decade, non-invasive methods for aneuploidy detection have been explored. The most successful approach involves analyzing the cell-free DNA (cfDNA) released by the embryo into the culture medium. The main objective of this study is to examine the technical feasibility of this new approach called non-invasive PGT-A or niPGT-A. In addition, as an exploratory objective, the impact of the niPGT-A results on clinic outcomes will be assessed. Methods: This was a multicenter, international study that included 716 patients and 2539 blastocysts (ClinicalTrials.gov: NCT03520933). Each embryo was cultured following a specific protocol for niPGT-A. Individual spent blastocyst medium (SBM) and trophectoderm (TE) biopsy were obtained, analyzed, and compared to assess concordance. In a subset of embryos, the comparison also included an inner cell mass (ICM) biopsy. Clinical outcomes from the embryo transfers performed (all based on the TE result) were registered, and results were analyzed blindly regarding the impact of aneuploidies in the culture medium. Results: The concordance rate between SBM and TE was 79.1% (range: 74.1–82.1; cycles with autologous oocytes). This value increased to 87.0% when comparing SBM and ICM. Applying an adapted embryo culture protocol to collect the SBM for niPGT-A did not affect blastocyst quality. Analysis of the embryo transfers performed (n = 265) revealed a trend towards lower miscarriage rate in blastocysts where both TE and SBM were concordant and euploid (13.0%), compared to blastocysts with a euploid TE and an aneuploid SBM (22.2%). Conclusions: The results obtained show a high concordance between the SBM and TE biopsies. Although additional refinement of the technique would further increase niPGT-A’s performance, the results obtained support the potential use of this non-invasive approach for aneuploidy detection. The high concordance of the cfDNA present in the SBM with the corresponding ICM biopsy and the miscarriage rate observed in cases with an aneuploid SBM, despite the euploid TE results, also support niPGT-A’s capacity to assess embryo aneuploidies and its potential as a prioritization system for selecting blastocysts to transfer. This approach could hold special interest in patients with no PGT-A indications, couples that prefer not to biopsy their embryos or those who do not have access to invasive PGT-A.


  • Top Cited Papers
    Open Access

    Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization

    by Baris R. Mutlu, Sabrina C. Civale, Joshua Diettrich, Neha Gupta, Thomas Barber, Mitchel Sayare, Alan S. Penzias, Michael M. Alper, Thomas L. Toth, Ravi Kapur, et al.

    Infertility is a global health challenge affecting millions worldwide, and in vitro fertilization (IVF) remains the main treatment option. The increasing demand for IVF necessitates innovations that improve access, efficiency and outcomes. To address this need, we developed a microfluidic device (FIND-Chip) that automates the isolation and denudation of oocytes from follicular fluid (FF), a critical step in IVF workflow. In a clinical study involving 582 patients from four IVF centers, FIND-Chip was utilized to perform automated oocyte recovery from FF and revealed that in more than 50% of the cases functional and mature oocytes are inadvertently discarded under current clinical practice. These undetected oocytes successfully developed into high-quality blastocysts, thereby substantially expanding the embryo pool available for patients’ treatment. Notably, an oocyte that was retrieved by FIND-Chip from a clinically screened and discarded FF sample led to a live birth, highlighting the potential of microfluidic automation to enhance IVF success rates.


  • The impact of endometrial fluid on single euploid frozen embryo transfers, to cancel or not?

    by Karishma Patel, Denny Sakkas, Brittany Morse, Daniel W Duvall, Alan Penzias, Denis A Vaughan

    STUDY QUESTION: What is the impact of endometrial fluid (EF) on single, euploid frozen embryo transfer (FET) cycles on live birth rate (LBR) and is cycle cancellation for EF a worthwhile intervention? SUMMARY ANSWER: The LBR of single euploid FETs was significantly lower by 20.2 percentage points when EF was persistent on the day of decision for progesterone start/trigger, but despite the lower LBR, cycle cancellation may not confer an improved chance at live birth. WHAT IS KNOWN ALREADY: The incidence of EF in cycles ranges from 3% to 8%, thus, only a few small studies have been performed to evaluate its impact. Existing literature generally concludes that the presence of EF leading up to an embryo transfer is detrimental to successful implantation, however, these studies examined untested embryos. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study was performed at a single, academically affiliated infertility center in the USA from January 2014 to December 2022. Inclusion criteria comprised patients who underwent their first IVF cycle, had pre-implantation genetic testing for aneuploidy performed by trophectoderm biopsy, had at least one euploid embryo, and were undergoing their first FET. Cycles were subdivided into three groups: no EF present in the cycle (no EF group), EF present but resolved prior to the day of decision for progesterone start/trigger (EF resolved group), and lastly, EF persistent on the day of decision for progesterone start/trigger (EF persistent group). Clinical outcomes were compared between the groups. In a secondary analysis, all single, euploid FET cycles that were cancelled due to EF were identified. The first subsequent completed single, euploid FET during the same study period was identified and analyzed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Four thousand three hundred eight FET cycles met inclusion criteria. Four thousand one hundred forty documented no EF, 108 documented EF that resolved, and 60 documented EF that persisted. The primary outcome was LBR per ET. A logistic regression analysis was performed adjusting for baseline characteristics (age, BMI, gravidity, parity, reason for infertility) and cycle characteristics (method of fertilization, protocol, endometrial thickness achieved during FET, embryo grade/day cryopreserved). In our secondary analysis, 90 single, euploid FET cycles were identified as cancelled specifically due to the presence of EF. Following these 90 cancelled cycles, there were 58 cycles that were identified as the first subsequent completed FET after cancellation. For the first subsequent completed single, euploid FET after index cycle cancellation, the presence of EF and overall LBR were recorded. MAIN RESULTS AND THE ROLE OF CHANCE: When EF was present, but resolved prior to decision for progesterone start/trigger, the LBR was 9.4 percentage points lower compared to the no EF group, however, this did not reach statistical significance (49.1% vs 58.5%, aOR 0.71 (95% CI 0.47, 1.05)). When EF was persistent on ultrasound on day of decision for progesterone start/trigger, the LBR was significantly lower by 20.2 percentage points when compared to the no EF group (38.3% vs 58.5%, aOR 0.50 (95% CI 0.28, 0.88)). Of 58 subsequent FET cycles identified after initial FET cancellation, 23 demonstrated EF recurrence (but were not cancelled). The overall LBR for all 58 subsequent cycles was 39.7% which was not significantly different from the EF persistent group (aOR 0.99 (95% CI 0.38, 2.64)). LIMITATIONS, REASONS FOR CAUTION: The retrospective, single center design may limit generalizability. Analysis of only euploid embryos introduces selection bias. Challenges of studying EF include the variable and unknown etiology of EF and non-uniform documentation of quantity/measurement of EF. Given the low incidence of EF, the sample sizes are small in the EF groups but are similar in size to previous studies. Power analysis was conducted and to achieve an 80% chance of finding a 10% difference in LBR, 385 patients would be needed in each group. In light of the actual LBR difference of 20.2 percentage points (58.5% vs 38.3%), our sample size of 60 patients in the EF group provided an 88% chance of finding a statistically significant difference. WIDER IMPLICATIONS OF THE FINDINGS: The LBR was 9.4 percentage points lower when EF resolved and 20.2 percentage points lower when EF was persistent. We identified a small cohort of subsequent cycles after initial cycle cancellation and the LBR achieved in these cycles was similar to the LBR in the index transfer cycle if the transfer was performed even in the setting of persistent EF at time of progesterone start/trigger; perhaps if EF is persistent, cycle cancellation may not confer an improved LBR. Overall, many cases of EF likely result from underlying endometrial pathology. Patients should be counseled accordingly. STUDY FUNDING/COMPETING INTEREST(S): No funding was used for this study. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

  • 40th anniversary of Human Reproduction: reflecting on four decades of scientific excellence

    by Christopher L R Barratt, Kirstine Kirkegaard, Denny Sakkas, Lauren A Wise, Andrew C Williams


  • Open Access

    Capturing aberrant cell behaviors producing defects in human embryos via live imaging

    by Hiroki Akizawa, Ana Domingo-Muelas, Maria Pardo-Figuerez, Blake Hernandez, Goli Ardestani, Robin M. Skory, Marta Venturas, Piotr Tetlak, Stephanie Bissiere, Denny Sakkas, et al.

    The generation of human embryos in vitro has revolutionized reproductive medicine, and also made it possible to study fundamental aspects of early human development. However, human preimplantation embryos often display an array of morphological defects associated with poor development and implantation. Here, we used live-embryo imaging and computational analysis to capture how these defects can be produced in real time. We record various forms of mitotic errors including lagging chromosomes producing micronuclei, multipolar spindles causing abnormal chromosome organization recapitulated by daughter cells, and uncontrolled scattering of condensed chromosomes. In addition, we capture abnormal cleavage furrow dynamics during cytokinesis producing binucleated and enucleated cells. Finally, we find cells with disrupted mitotic progression ultimately leading to blebbing and fragmentation. Thus, these results document specific aberrant cell behaviors producing morphological defects in real time, and indicate that errors during mitosis and cytokinesis represent a major cause of developmental failures in human embryos.


  • Mitochondrial metabolism influences meiotic maturation in human oocytes of young and advanced maternal age women

    by Sara Pietroforte, Marion Martins, Montserrat Barragan, Elena Ibañez, Rita Vassena, Mina Popovic, Tim Sanchez, Denny Sakkas, Filippo Zambelli

    STUDY QUESTION: Is there a relationship between the mitochondrial activity and the meiotic progression of oocytes from germinal vesicle (GV) to metaphase II (MII) stages in young and advanced maternal age (AMA) women? SUMMARY ANSWER: Poor mitochondrial metabolism impairs the meiotic progression of human GV oocytes, contributing to a lower oocyte maturation capacity of AMA oocytes. WHAT IS KNOWN ALREADY: AMA oocytes are characterized by diminished quality, mostly due to the higher rates of chromosomal segregation errors occurring during meiosis I. Another hallmark of AMA oocytes is impaired mitochondrial metabolism. Studies in mice have suggested a link between metabolic dysfunction and meiotic failure, but this relationship has not been fully elucidated in humans. Metabolic dynamics can be visualized by indirect measurements through mitochondrial staining and quantified more directly using fluorescence lifetime imaging microscopy (FLIM). This live-imaging approach can generate metabolic timelapse profiles of oocytes throughout meiosis. In the present study, we explored mitochondrial distribution and functionality in human oocytes at the GV and MII stages, obtained from young and AMA women, to establish the role of mitochondrial metabolism in meiosis progression. STUDY DESIGN, SIZE, DURATION: A total of 340 GV oocytes from young (≤34 years) and AMA (>37 years) women were included in the study. Denuded GVs were matured in vitro in G2-plus medium for 30 h. Maturation was determined by the presence of the extruded first polar body (PB1). The collected oocytes were processed for mitochondrial protein imaging (n = 80), or for live imaging (n = 171). Moreover, 89 oocytes were used for loss-of-function analysis by treating young GVs with 1 μM trifluoromethoxy-carbonylcyanide-phenylhydrazone (FCCP) for 30 min before in vitro maturation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The proteins dihydrolipoamide-S-acetyltransferase (D-LAT) and translocase-of-outer mitochondrial-membrane (TOMM20) were analyzed in young and AMA oocytes by immunofluorescence to assess mitochondrial activity and localization, respectively. Fluorescence mean intensities (arbitrary-unit, AU) were quantified with ImageJ and compared by t-test; maturation rates were compared by chi-squared test. FLIM comprehensive metabolism (NAD(P)H; FAD+) was taken at GV stage. Different FLIM parameters (fluorescence intensity, fraction bound, short/long lifetime) and the Redox ratio (NAD(P)H intensity/FAD+ intensity) were evaluated. MAIN RESULTS AND THE ROLE OF CHANCE: The findings revealed that active mitochondria are specifically localized in the subcortical area, while mitochondria in general are distributed across the whole oocyte. This pattern was substantially maintained in AMA oocytes, which were in turn characterized by a lower mitochondrial activity (D-LAT intensity of 78 614 ± 58 534 AU in young, 12 517 ± 10 187 AU in AMA, P = 0.003), while a lower number of mitochondria was observed In AMA patients but the difference did not reach statistical significance (TOMM20 intensity of 61 674 ± 24 322 AU in young, 32 186 ± 33 414 AU in AMA, P = 0.195). Using non-invasive FLIM, we assessed the metabolic dynamics of maturing oocytes (Redox ratio in young 2e + 00 ± 0.15, in AMA 1e + 00 ± 0.16, P = 2.969e-05), confirming a similar pattern observed by immunofluorescence. Specifically, FLIM microscopy revealed that GV oocytes from young women slightly increased their metabolism, by 4% on average, after the GV breakdown, and the increase was very consistent across different oocytes. On the contrary, in AMA maturing oocytes, little to no increase in metabolism was observed; they were characterized instead by higher variability, and more AMA oocytes failed to successfully reach the MII stage [AMA oocytes (62.3%; 38/61) compared with young oocytes (86.3%; 63/73; P = 0.002). These differential trends observed in AMA oocytes compared to the young oocytes suggest that impaired metabolic activity significantly compromises maturation capacity, revealing a functional link between adequate metabolic levels and successful meiosis progression. LIMITATIONS, REASONS FOR CAUTION: Maturation rates were assessed by the presence of an extruded PB1 and variations in spindle assembly timings may have been overlooked. The quantification of mitochondrial activity in loss-of-function studies was assessed only by immunofluorescence staining. Additionally, the oocytes included in the present study were collected from women who underwent ovarian stimulation and may not faithfully recapitulate physiological maturation. WIDER IMPLICATIONS OF THE FINDINGS: Our findings demonstrate the presence of a functional link between oocyte mitochondrial metabolism and meiosis progression, which may contribute to the decline of oocyte quality with aging. Overall, we provided evidence to understand the biological mechanisms in mitochondrial metabolism that might contribute to driving the decay in oocyte quality in AMA women. STUDY FUNDING/COMPETING INTEREST(S): This project received intramural funding from the Eugin Group and funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860960. T.S. is a former owner and former stock owner of Optiva Fertility Inc (company closed) and filed two patents for Optiva Fertility Inc (both abandoned). D.S.: Presenter EMD Senoro and Dep. Editor of Human Reproduction. All of the other authors (S.P., M.M., M.B., E.I., M.P., R.V., and F.Z.) have no conflicts of interest to declare. All of the authors contributed substantially to the manuscript and approve its submission. TRIAL REGISTRATION NUMBER: N/A.


  • A high proportion of immature oocytes in a cycle cohort does not compromise embryo development or live birth rates after ICSI

    by Veda Sripada, Denny Sakkas, Denis Vaughan, Brittany Morse, Yuval Fouks

    STUDY QUESTION: Does a high proportion of immature oocytes impact embryo development and live birth rates in IVF–ICSI cycles? SUMMARY ANSWER: While a high proportion of immature oocytes is associated with lower blastocyst formation and reduced preimplantation genetic testing for aneuploidy (PGT-A) utilization, live birth rates remain comparable when key confounders—such as age, BMI, gonadotropin dosage, and metaphase-II (MII) count—are balanced, but cycles with a very low MII proportion resulted in fewer embryo transfers, which is quantitatively limiting, even if embryo quality appears unaffected. WHAT IS KNOWN ALREADY: Previous studies have linked a lower proportion of mature oocytes (MII) to decreased fertilization rates, abnormal embryo development, and lower pregnancy and live birth rates. However, it remains unclear whether these outcomes are due to quantitative limitations (fewer mature oocytes available) or qualitative deficiencies (intrinsic oocyte quality issues). The impact of high proportions of immature oocytes on downstream IVF outcomes remains controversial. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study at a single academically affiliated fertility clinic between December 2014 and December 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: 22 117 patients undergoing IVF–ICSI cycles were categorized into three groups based on the proportion of mature (MII) oocytes: very low MII proportion (≤0.25), low MII proportion (≤0.5), and 100% MII oocytes. Propensity score matching (PSM) was applied in two phases: first, adjusting for age, BMI, gonadotropin dosage, and anti-Müllerian hormone levels; second, adjusting for age, BMI, gonadotropin dosage, and MII count. MAIN RESULTS AND THE ROLE OF CHANCE: Cycles with a very low MII proportion (≤0.25) had significantly lower blastocyst formation—mean 1.32 (SD 2.77; 95% CI: 1.03–1.61) versus 3.10 (SD 3.22; 95% CI: 2.77–3.43; P < 0.001)—and reduced PGT-A utilization—mean percent PGT-A normal 34% (95% CI: 30–38%) versus 40% (95% CI: 36–44%; P < 0.001). However, after PSM, live birth rates per an embryo transfer did not differ significantly between very low MII and perfect MII groups for both cryopreserved transfers (41.6% versus 30%, P = 0.68) and fresh embryo transfers (46.1% versus 38%, P = 0.69). The low MII proportion group (≤0.5) showed a trend toward lower cryopreserved transfer rates (44% versus 53%, P = 0.05), while fresh transfer rates remained comparable (30% versus 26.6%, P = 0.55). LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective nature and reliance on electronic medical records. While PSM effectively reduced confounding, inherent oocyte quality markers (e.g. mitochondrial function) were not directly measured. Additionally, the non-uniform distribution of MII proportions across groups may have influenced statistical power. WIDER IMPLICATIONS OF THE FINDINGS: These results underscore the importance of personalized ovarian stimulation protocols to optimize mature oocyte (MII) yield and support successful outcomes, even in patients with high proportions of immature oocytes. STUDY FUNDING/COMPETING INTEREST(S): The study was not funded. No competing interests TRIAL REGISTRATION NUMBER: N/A.